Roland Andersson is professor of surgery and vice dean for the medical faculty at Lund University. He is co-founder of Reccan Diagnostics AB, as well as several other biotech companies, including Probi Ltd and Bioactive Polymers in Lund Ltd. Professor Andersson is also CEO of Nordic Biotechnology Ltd and member of the board of Bioactive Polymers.
Daniel Ansari is co-founder of Reccan Diagnostics AB and holds the position as scientific coordinator. Dr Ansari is employed as researcher at Lund University as well as surgeon at SUS, Skåne University Hospital and holds a MD and a PhD from Lund University. He has extensive research experience in the field of surgery and diagnostics, with special focus on translational research in pancreatic cancer.
György Marko-Varga is professor and head of the division of clinical protein science and imaging at Lund University, professor at Tokyo Medical University in Japan as well as co-founder of Reccan Diagnostics. Prof. Marko-Varga has almost twenty years of experience from Big Pharma and a long list of filed patent applications. His access to novel technological platforms and biobanking is of fundamental value for Reccan Diagnostics.
Annette Säfholm is project and communications manager at Idogen AB, a cell therapy company in Lund listed on AktieTorget. She holds a PhD in Experimental pathology (breast cancer) from Lund University, a project manager certification (Prince2) and eight years’ experience in project management and business development from both private companies and the health care sector.